EUCTR2010-022766-27-HU进行中（未招募）不适用
A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF MULTISTEM (PF-05285401) IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK0 个研究点目标入组 128 人开始时间: 2011年12月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 128
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject eligibility should be reviewed and documented by an appropriately qualified member of the investigator’s study team before subjects are included in the study. The selection of patients is based on the data available from Screening. Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
- •1.Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
- •2. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, lifestyle guidelines and other study procedures.
- •3. Subject must be at least 18 years of age.
- •4. Males and females with a documented diagnosis (endoscopic or radiographic) of UC =6 months prior to screening.
- •5. For Cohort 1 and 2 only: Active moderate-to-severe UC defined as Mayo score of =6 and <11.
- •6. For Cohort 3 only: Active moderate-to-severe UC defined as Mayo score of =6.
- •7. Modified Baron endoscopic score of =2 determined within 21 days of first dosing for Cohort 1 and within 7 days of first dosing for Cohorts 2 and 3 (flexible sigmoidoscopy unless surveillance colonoscopy clinically indicated).
- •8. Subjects must have failed or be intolerant (as determined by the investigator) of at least one of the following treatments for UC: Oral corticosteroids, azathioprine or 6-mercaptopurine (6-MP), or anti-tumor necrosis factor (TNF) therapy, eg, infliximab or adalimumab.
- •9. Subjects currently receiving the following treatment regimens for UC are eligible providing they are on stable dose for designated period of time:
- •a. 5-ASA or sulfasalazine stable dose for at least 3 weeks prior to Day 1 and during the study treatment period.
- •b. Corticosteroids or equivalent at a stable dose for at least 2 weeks prior to Day 1 study visit (Prednisolone =25 mg/day, or equivalent). NOTE: Tapering of corticosteroids or equivalent may only commence at Week 8 (see Concomitant Medications” section of the protocol).
- •c. Antibiotics (eg, metronidazole, rifaximin) stable dose for at least 2 weeks prior to Day 1 study visit and during the study treatment period ie, up to Week 8.
- •d. Rectally administered formulation of corticosteroids or 5-ASA stable dose for at least
- •2 weeks prior to Day 1 study visit and during the study treatment period ie, up to Week 8.
- •e. Methotrexate (up to 15 mg/week subcutaneously), azathioprine (up to 2.5 mg/kg/day) and 6-mercaptopurine (up to 1.5 mg/kg/day) stable for at least 2 months prior to Day 1 study visit and during the study treatment period, ie, up to Week 8.
- •NOTE: excluded medications include anti-TNF therapies used within 8 weeks of Day 1 study visit or cyclosporine, mycophenolate, or tacrolimus used within 4 weeks of Day 1 study visit as described in the exclusion criteria.
- •10.Subjects willing to use double contraception during the study treatment period and until completion of follow-up procedures ie, Week 52: (a) If the subject is a sexually active woman of childbearing potential, she and her male partner are required to simultaneously use 2 effective contraceptive methods as listed in Section 4.4.2 of the protocol. Female subjects who wish to use non-hormonal contraception must have done so for at least 14 days prior to the Day 1 study visit. (b) Non-vasectomized males with female partners of child bearing potential must be willing to use a condom in addition to ha
排除标准
- •Subjects presenting with any of the following will not be included in the study:
- •1. Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.
- •2. Abnormal organ and marrow function as defined: (a) leukocytes <4,000/µL. (b) Platelets <150,000/µL. (c) AST (SGOT) or ALT (SGPT) >3x institutional upper limit of normal. (d) Bilirubin >upper institutional limit of normal. (e) Creatinine >1.2 mg/dL.
- •3. Diagnosis of indeterminate colitis, or clinical findings suggestive of Crohn’s disease, including Crohn’s enterocolitis, ischaemic colitis, radiation colitis, diverticular disease associated colitis as well as microscopic colitis.
- •4. Subjects with UC, which is confined to a proctitis defined as inflammation limited to less than 15 cm from the anal verge on a flexible sigmoidoscopy.
- •5. Subjects who meet Truelove-Witts criteria for severe UC. Diarrhea >6 times/day, bloody and any one of the items: (a) Hemoglobin 75% or below of normal value. (b) Evening temperature >37.5?C. (c) Pulse rate >90 beats/min. (d) ESR >30 mm/h.
- •6. Subjects who have received i.v. steroids or TPN or have been hospitalized due to UC within 3 weeks prior to screening.
- •7. Subjects displaying clinical signs of toxic megacolon, ischemic colitis or fulminant colitis.
- •8. Known allergies to bovine or porcine products, dextran or H1 blockers.
- •9. 9. Known intolerance to corticosteroids.
- •10. Subjects who have previously participated in any study of an allogeneic cell therapy, with the exception of erythrocyte transfusions.
- •11. Subjects who have received any investigational drug or device within 3 months (or as determined by the local requirement, whichever is longer) prior to Day 1 study visit.
- •12. History of symptomatic obstructive strictures, an ostomy, extensive bowel resection
- •(>100 cm) or short bowel syndrome.
- •13. History of bowel surgery within 6 months prior to Day 1 study visit.
- •14. Subject who have had surgery as a treatment for UC or, in the opinion of the investigator, are likely to require surgery within 16 weeks of informed consent.
- •15. Subjects diagnosed with primary sclerosing cholangitis.
- •16. Subjects with active inflammatory eye disease.
- •17. Subjects with spondylarthropathy and active musculoskeletal manifestation.
- •18. Subjects with active pyoderma gangrenosum or erythema nodosum lesions.
- •19. Subjects with clinically significant pulmonary disease (eg, subjects with COPD GOLD stage III or IV).
- •20. Subjects with NYHA class IV congestive heart failure.
- •21. Subjects with active systemic or severe local infections.
- •22. Fecal culture indicating presence of pathogenic infection; positive C. difficile toxin, or positive stool ova and parasite exam.
- •23. Subjects likely to require any type of surgery within 16 weeks from informed consent.
- •24. Known collection or abscess on MRI of the pelvis.
- •25. Pregnant or lactating women.
- •26. History of alcohol or drug abuse with less than 6 months of abstinence prior to Day 1 study visit.
- •27. Screening 12-lead ECG that demonstrates clinically relevant abnormalities which may affect subject safety or interpretation of study results.
- •28. Subjects with a temperature of 38?C (100.4?F) or higher at screening.
- •29. Subjects with malignancies or with a history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin.
- •30. Significant trauma or major surgery within 4 we
研究者
相似试验
进行中（未招募）
1 期
A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RECOMBINANT HUMAN PLASMA GELSOLIN (RHU-PGSN) ADDED TO STANDARD OF CARE FOR TREATMENT OF SUBJECTS WITH SEVERE COVID-19 PNEUMONIAsevere COVID-19 pneumoniaMedDRA version: 23.0Level: LLTClassification code 10084401Term: COVID-19 respiratory infectionSystem Organ Class: 100000004862EUCTR2020-002460-31-ROBioAegis Therapeutics, Inc.60
进行中（未招募）
1 期
A Clinical Trial to evaluate AL002 in Participants with early Alzheimer's DiseaseEarly Alzheimer’s DiseaseMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-001476-11-DEAlector Inc.328
已完成
不适用
A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ANTROQUINONOL IN HOSPITALIZED PATIENTS WITH MILD TO MODERATE PNEUMONIA DUE TO COVID-19-J128 Other viral pneumoniaOther viral pneumoniaJ128PER-090-20Golden Biotechnology Corporation,23
进行中（未招募）
不适用
Study of safety and effectiveness of human-derived stem cells (multistem, also known as PF-05285401) in the treatment of ulcerative colitisEUCTR2010-022766-27-SKPfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK128
进行中（未招募）
1 期
A Clinical Trial to evaluate AL002 in Participants with early Alzheimer's DiseaseEarly Alzheimer’s DiseaseMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-001476-11-ITAlector Inc.265